期刊文献+

Clinical Review of Iressa for the Treatment of NSCLC

Clinical Review of Iressa for the Treatment of NSCLC
下载PDF
导出
摘要 Following development of basic science and the advancement of tumor molecular biology, molecular-target therapy has evolved as a new field for cancer treatment. The agents used act at specific target points such as receptors, kinases and signal transduction systems which are related to tumor growth. These actions result in inhibting proliferation, metastasis, vascularization, and promoting tumor apoptosis. Iressa (gefitinib) which is used for the treatment of NSCLC is a small molecular weight agent acting by inhibition of epidermal growth factor receptor-tyrosine kinase. Iressa was the first approved agent for target therapy for the treatment of NSCLC. This article focuses on the results from clinical trials and the potential of Iressa for the treatment of NSCLC.
作者 Gang Cheng
出处 《Chinese Journal of Clinical Oncology》 CSCD 2005年第5期829-833,共5页 中国肿瘤临床(英文版)
关键词 target therapy NSCLC iressa (gefitinib). 肿瘤治疗 分子生物学 信号转换 肿瘤生长
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部